Dr. Lukas Imberg is a former PhD student of the group, having defended his doctoral thesis in 2022. His research focused on the synthesis and biological evaluation of acylated 1H-1,2,4-triazol-5-amines and 1H-pyrazol-5-amines as inhibitors of human blood coagulation factors FIIa and FXIIa. He is currently working at Sanofi.